print back
IDET - Innovazione Diagnostica e Terapeutica

The Excellence Centre for diagnostic and therapeutic innovation, IDET, is active in molecular medicine and pursues the aim of the development of technologies and molecules with diagnostic and therapeutic applications in immunology, oncology, genetics and neurobiology.

Do you want to print an overview or a detailed profile?

Adress

Viale Europa 11
25123 Brescia
(Lombardy)

Telephone

+39 030 371 73 04

Fax

+39 030 370 11 57

World Wide Web

www.med.unibs.it

 


Technology transfer

Inclusion in EU project

  • 6° Programma quadro

National projects

  • MIUR
  • Fondazione Cariplo

Projects with Italian and Foreign Companies

  • Project "Screening von antiangiogenetischen Präparaten"
  • Project "Characterisation of teh activity and the effect mechanism of C5aR inhibitors and of dual CXCR1 and C5aR inhibitors"
  • "Molecular Aspects of the inflammation-inhibiting activity of DF1681: Definition both of a cell model for the identification of a molecular target and also the effects expressed on the Transcriptome Project and on that, wich is induced by IL-8 in neutrophil granulocytes”
  • "Evaluation of the Effects of the of the IL6-Chimera on Cells and Animal Models with regard to Neuro-Protection and Remyelination” Project

International patents:

These Projects have facilitated the depositing of the following international patents:

  • Procedure for the identification of links, the regulation of immune and inflammation responses and their therapeutic application
  • PTX3 as early marker for heart and brain blood vessel illnesses
  • 6RIL6-Chimera for the treatment of neurovegetative illnesses
  • Application of long Pentraxin PTX3 for the preparation of a preparation for the treatment of cancer illnesses, which are connected with a changed activation of the growth factor FGF2
  • Application of long Pentraxin PTX3 for the preparation of a medical preparation for the treatment of cancer illnesses, which are connected with a changed activation of the growth factor FGF8
  • Application of sulphated bacterial polysaccharides suitable for the inhibition of the angiogenesis
  • The cell adhesion protein Jam as a target for the development of new therapeutic inoculation strategies

Contacts to Germany already exist

No

Contacts to German companies are welcomed in the (following) areas

Medicinal biotechnologies in immunology, oncology, molecular and genomic genetics and in neurosciences.